1. Home
  2. NEXN vs PRME Comparison

NEXN vs PRME Comparison

Compare NEXN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

SELL

Current Price

$8.66

Market Cap

520.5M

Sector

Technology

ML Signal

SELL

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$3.70

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NEXN
PRME
Founded
2007
2019
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
520.5M
526.0M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
NEXN
PRME
Price
$8.66
$3.70
Analyst Decision
Buy
Buy
Analyst Count
9
13
Target Price
★ $14.54
$7.39
AVG Volume (30 Days)
564.2K
★ 5.6M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.18
EPS
★ N/A
N/A
Revenue
N/A
★ $4,632,000.00
Revenue This Year
$9.39
$150.97
Revenue Next Year
$9.89
$18.06
P/E Ratio
$9.64
★ N/A
Revenue Growth
N/A
★ 55.28
52 Week Low
$5.60
$2.67
52 Week High
$11.30
$5.91

Technical Indicators

Market Signals
Indicator
NEXN
PRME
Relative Strength Index (RSI) 46.81 46.82
Support Level $8.34 $2.94
Resistance Level $10.58 $4.80
Average True Range (ATR) 0.56 0.46
MACD 0.05 -0.11
Stochastic Oscillator 34.92 10.49

Price Performance

Historical Comparison
NEXN
PRME

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from United States.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: